ATTENUATED INFLUENZA VIRUS USEFUL AS VACCINE

Abstract: A negative-sense single stranded RNA virus attenuated by replacement of the poly U track in a genomic nucleic acid by a poly A track which is capable of being copied to provide a poly U tail for mRNA transcribed from the nucleic acid. The virus is typically influenza virus. The virus may be incorporated into a vaccine or used as a helper virus.

Description: ATTENUATED INFLUENZA VIRUS USEFUL AS VACCINE The present invention relates to modified viruses which can be used in a vaccine. In particular such viruses can be influenza viruses. Modified viruses of the invention also include recombinant attenuated viruses suitable for use as viral vectors for expression of heterologous sequences in target cells. Attenuated viruses can be used to immunise against the diseases caused by the equivalent wild-type viruses. Vaccines made from attenuated viruses are often superior to vaccines containing dead virus or viral proteins produced by recombinant techniques. For example in the case of influenza present inactivated influenza virus vaccines provide only limited protection. Previous efforts to provide a safe, live attenuated influenza vaccine have focussed primarily on cold-adapted influenza viruses. Thus, attenuated influenza viruses have previously been obtained by extensively passaging influenza virus at low temperatures. As a result of adaptation to growth at low temperature, influenza viruses which have lost their ability to replicate at higher temperatures (about 39 °C) are obtained. The replication of such cold-adapted (CA) viruses is only slightly restricted in the cooler upper respiratory tract, but highly restricted in the warmer lower respiratory tract, the major site of disease-associated pathology. Sequence comparisons between wild-type and CA influenza viruses have revealed both silent mutations and non-silent mutations leading to amino acid changes predominantly in the coding regions of gene segments. Most amino acid changes were found to be the result of point mutations. The genetic instability of point mutations, and the level of immunogenicity of CA influenza viruses, remain as perceived potential problems in use of CA influenza viruses as vaccines for worldwide general use. Genetic engineering may be used to modify viruses in order to attenuate them. The modification must weaken the virus without rendering it incapable of infecting host cells. The inventors have identified such a modification which affects the way that mRNA is processed in host cells, and therefore can be used for any negative-sense single stranded RNA virus that uses a similar polyadenylation strategy, and in particular influenza viruses. They have found that when a poly U track in a viral gene is replaced with a poly A track functional mRNA is still transcπbed from the gene Viruses with such modifications have been found to be attenuated The modifications are also stable as point mutations in the poly A track disrupt transcription from the gene Poon et al (1) discloses that poly A track in an influenza vRNA segment can be copied to provide a poly U tail for mRNA transcribed from the segment However this paper does not describe the characteristics of such mRNA, or suggest that the replacement of a poly U track in the genomic nucleic acid of a virus can be used to produce a functional attenuated virus The invention provides a negative-sense single stranded RNA virus attenuated by replacement of the poly U in a genomic nucleic acid by a poly A track which is capable of being copied to provide a poly U tail for mRNA transcπbed from the segment The virus is typically of the family Orthomyxoviridae (e g influenza virus), Paramyxoviridae (e g parainfluenza virus, mumps virus, measles virus or respiratory syncytial virus), Rhabdovindae (e g rabies virus or vesicular stomatitis virus) , Filoviridae (e g Marburg virus or Ebola virus), Bunyavirtdae or Arenaviridae The virus may have one or more genomic segments A negative stranded RNA virus with several genomic segments is exemplified by influenza virus (1) The influenza virus may be influenza A, B or C In one embodiment the virus is one in which the poly A track is copied by a reiterative mechanism Generally in such a mechanism the polymerase repeatedly 'slips back' when transcribing the poly A track allowing formation of a poly U tail in the mRNA which is longer than the poly A track Preferred viruses which use such a reiterative mechanism are influenza viruses, and of these influenza A virus is particularly preferred The virus is attenuated and therefore will cause reduced disease symptoms (compared to the wild-type virus) when it is administered to a host Thus one way of assessing attenuation is by measuring pathogenicity in a mouse model (e g as described in Examples 7) Generally the virus of the invention has a reduced ability to replicate in any, some or all of its natural host cells or in cell lines which the virus is able to infect One way this can be measured is the reduction in virus titre when the virus is used to infect such cells Typically the virus will exhibit at least a 0 3 log reduction, for example at least a 0 5 log, 0 8 log , 1 log , 2 log , 5 log, 10 log or more reduction in titre Generally the virus will be able to replicate to some degree in the host cell, l e be able to produce infectious daughter viruses In the case where the virus is an influenza virus Madin-Darby bovine kidney (MDBK) cells, Madin-Darby canine kidney cells or Vero cells can be used to measure the reduced ability of the virus to replicate Generally in the nucleic acid all of the undines in the poly U track which can be copied to form the poly A tail are replaced by the same number, a reduced number or an increased (e g 1, 2, 3 or more fewer or greater) adenosines In the case of an influenza virus the entire U 6 track is generally replaced by an A 5 A 6 A 7 A 8 A 9 , A 10 track or a track comprising more than 10 adenosines such as 1 1 to 15 adenosines or more Typically the nucleic acid will differ from the equivalent wild-type nucleic acid by 4, 5, 6, 7 to 10, 10 to 20 or more mutations (which can be insertions, deletions or substitutions) Such mutations may typically be at the 5 ' and/or 3 ' terminus Typically the nucleic acid is homologous to and/or capable of hybridising to the equivalent wild-type genomic segment In one embodiment the nucleic acid is a chimera of fragments from different viruses In the case of influenza the nucleic acid may be a chimera of fragments from an influenza A and/or B and/or C virus The nucleic acid is capable of being expressed in a host cell to produce at least one mRNA with a poly U tail Generally proteins encoded by the nucleic acid (and by this mRNA) are expressed at reduced levels in the cell (compared to the equivalent mRNA with a poly A tail) At least one of the proteins is one which causes attenuation when expressed at levels below the level at which they are expressed by the wild-type virus The proteins are typically wild-type proteins or functional equivalents which have at least some of the activity of the wild-type proteins The proteins are typically structural proteins (e g a coat protein), non-structural proteins or enzymes (e g a polymerase) The virus may contain 1, 2, 3, 4 or more nucleic acids in which the poly U track has been replaced by a poly A track Where the virus is an influenza virus the nucleic acid is typically a mutated native influenza virus genomic segment This segment may encode the influenza proteins: PB 1, PB2 or PA polymerase proteins, the nucleoprotein (NP), the matrix proteins Ml or M2, haemagglutinin (HA), neuraminidase (NA), NS l or NS2; or functional equivalents of any of these proteins. Preferably the segment encodes NA. A virus of the invention may additionally contain a heterologous coding sequence capable of being expressed in host cells. Such a heterologous coding sequence may encode an antigenic peptide or polypeptide capable of stimulating an immune response (either an antibody response or a cell-mediated immune response) to a pathogenic agent. Representative examples of such pathogenic agents are viruses, e.g. other influenza viruses or non-influenza viruses such as HTV, bacteria, fungi, parasites, eg. malaria parasites, and disease-causing cells such as cancer cells. For vaccinating purpose, a heterologous coding sequence may be provided in an attenuated virus of the invention encoding an antigen of a pathogenic agent or a modification thereof capable of stimulating an immune response. The heterologous coding sequence may be inserted into a viral gene to provide a fusion protein which retains the function of the parent viral protein. In the case of influenza virus one site which has previously been found to tolerate insertions of foreign antigens (epitope grafting) is the antigenic B site of HA. Antigenic site B of that surface protein consists of an exposed loop structure located on top of the protein and is known to be highly immunogenic. Manipulation of the HA gene of an influenza virus to insert a viral epitope in the HA protein B site has previously been reported (see again the studies of Muster et al. reported in 2 and the studies of Li et al. reported in 3). The same strategy has also previously been employed by Rodrigues et al. to express B- cell epitopes derived from a malaria parasite (4). Heterologous coding sequences for an antigenic polypeptide may also, for example, be preferably inserted into an influenza virus NA gene. Strategies for epitope grafting into influenza viral proteins have also previously been described, for example, in WO91/03552. Epitope grafting of a foreign sequence into an influenza virus protein may result in a non-functional chimeric viral protein and make the rescue of a viable transfectant virus impossible. A different strategy for expressing foreign sequences by recombinant influenza viruses, which may be applied to attenuated viruses of the present invention, involves the engineering of gene segments containing an additional open reading frame. A recombinant genomic segment may be constructed which provides an internal ribosome entry site for a heterologous coding sequence. This approach has previously been used, for example by Garcia-Sastre et al. to obtain an influenza virus vRNA segment which encodes both a truncated form of gp41 of HIV and NA (5). Alternatively, a heterologous coding sequence may be fused in frame to a viral protein coding sequence to encode a chimeric polyprotein capable of autoproteolytic protease cleavage to give the viral protein and a desired second polypeptide, e.g. a viral antigen. This strategy has been shown by Percy et al. to be suitable for expressing non-influenza proteins up to 200 amino acids in length (6). It will be appreciated that a recombinant attenuated virus of the invention may be employed as a vehicle for expression of heterologous coding sequences in target cells for a variety of therapeutic purposes in addition to vaccination. Such a recombinant virus may, for example, have a genomic segment encoding any of the following: - a cytokine such as an interferon or an interleukin, - a toxin, - a palliative capable of inhibiting a function of a pathogenic agent either directly or indirectly, e.g. a viral protease inhibitor - an enzyme capable of converting a compound with little or no cytotoxicity to a cytotoxic compound, e.g. a viral enzyme such as Herpes simplex thymidine kinase capable of phosphorylating purine and pyrimidine analogues to active toxic forms, - an antisense sequence, - a ribozyme. Sequences encoding such agents may be incorporated into an attenuated virus of the invention by any of the techniques previously referred to above in connection with providing attenuated viruses of the invention expressing foreign epitopes. A recombinant virus of the present invention may be employed for gene therapy. The nucleic acid discussed above in which the poly U track has been replaced by a poly A track, and DNAs capable of transcription to provide such a nucleic acid, also constitute additional aspects of the invention. The DNA may be capable of transcription to provide a nucleic acid of the invention in a prokaryotic or eukaryotic cell expression sytem or in any of the cells which the virus is capable of infecting (such as any such cells mentioned herein) The DNA may be the genome or part of the genome of a cell or virus. The DNA may be a vector, typically an expression vector The DNA may be in the form of a viral vector or a plasmid In the case of influenza a cDN A of a native influenza virus vRNA segment may be inserted into a plasmid flanked by an appropriate promoter and a restriction endonuclease site. The cDNA may then be subjected to site-directed mutagenesis by, for example, PCR-directed mutagenesis employing appropriate mutagenic primers to provide a sequence encoding the desired mutated vRNA segment for transcription. In the case where the virus is an influenza virus the nucleic acid of the invention may be complexed in vitro with influenza viral polymerase proteins and nucleoprotein to form a RNP complex which has all the components necessary for transcription and replication. Such RNP complexes, which constitute a still further aspect of the present invention, may be prepared in conventional manner as previously employed for incorporation of genetically-engineered influenza virus RNA genomic segments into RNA complexes for viral rescue in cells (7, 8, 9). RNP complexes of the invention may be transfected into cultured cells, e.g. MDBK cells, MDCK cells or Vero cells, again using conventional techniques. Methods commonly employed for this purpose include DEAE-dextran transfection and electroporation (10, 11). The invention also provides an ex vivo cell infected by a. virus of the invention. Such cells includes human and/or animals cells normally infected by influenza viruses. The cells may be of a single cell type or more than one type, e.g. cultured human or non-human animal cells of one or more than one type. They may be in vivo cells, e.g. cells of an animal model. The cells may be any of the types of cells mentioned below in relation to selection systems. These types of cells can be used in the method of making the virus described below. The virus of the invention may be made in a method comprising providing in a host cell the nucleic acid of the invention, and any other genomic nucleic acids which are required (for the virus to be viable) under conditions whereby the nucleic acids are packaged into a viral particle. Such conditions typically include the presence of the proteins required to form the viral particle The genomic nucleic acids may be provided in the host cell by plasmids In the case of influenza RNP complexes of the invention as hereinbefore described may be transfected into host cells that have previously been infected with an influenza helper virus to complement the RNP complexes and enable selection of the desired attenuated viral particles A number of helper virus-based cellular rescue systems for particular influenza virus genes have previously been described and have been reviewed by Muster and Garcia-Sastre (12) Such gene specific rescue systems are briefly summarized below Helper virus based influenza gene rescue systems Helper based rescue systems have been reported allowing the genetic manipulation of influenza A vRNAs for NA and HA surface antigens, the non- structural proteins, NP, PB2 polymerase protein and the M proteins NA gene specific rescue system The most commonly employed helper virus based influenza gene rescue system is limited to the NA of influenza A/WSN/33 virus (7, 8) This method is based on the observation that only influenza viruses with an NA gene from influenza A/WSN/33 are able to grow on MDBK cells in the absence of trypsin In this rescue system, the helper virus is a reassortant containing seven gene segments from influenza A/WSN/33 and a NA gene from a virus other than influenza A/WSN/33 Generally A/WSN-HK, which has an NA gene from influenza A/HK/8/68, is used as the helper virus In this system, the NA gene of influenza A/WSN/33 is transfected into cells infected with the helper virus The virus is then selected by growing on MDBK cells in the absence of exogenous proteases NA genes can also be rescued by using a NA-deficient mutant virus as a helper virus Such a helper virus requires exogenous neuraminidase to grow in tissue culture. The NA-gene is transfected into cells infected with the helper virus The virus is then selected by growing on cells in the absence of neuraminidase (13) NS gene specific rescue system A temperature-sensitive influenza virus with a defect in the NSl protein is used as the helper virus of a NS gene specific rescue system. The NS gene segment carries two overlapping genes coding for the NS 1 and NS2 proteins. This rescue system allows the rescue of a NS gene segment encoding an NS 1 protein which has activity at the non-permissive temperature. In this system, the NS gene segment which is to be rescued is transfected into cells infected with the temperature-sensitive virus. The virus with the transfected NS gene segment is selected by growing the virus at the non-permissive temperature as described by Enami et al. (14) and Egorov et al (26). PB2 gene specific rescue system A virus with an avian influenza A virus PB2 gene can be used as the helper virus in a PB2 gene specific rescue system. The avian influenza A virus PB2 gene restricts the replication of the helper virus in mammalian cells. Therefore, this rescue system can rescue a PB2 gene which allows replication of influenza virus in mammalian cells. The PB2 gene which is to be rescued is transfected into cells infected with the helper virus. The virus with the transfected PB2 gene is selected by growing the virus in mammalian cells. Subbarao et al. (15) have used such an avian influenza A virus PB2 gene based system to rescue the PB2 gene of wild-type influenza A/ Ann Arbor/6/60 virus. M gene specific rescue system An amantidine-sensitive influenza virus carrying an M gene of influenza A/equine/Miami/ 1/63 virus can be used as a helper virus of an M gene specific rescue system. The rescue system allows the rescue of an M gene which confers amantidine resistance to a virus. In this system, the M gene which is to be rescued is transfected into cells infected with the helper virus. The virus with the transfected M gene is selected by growing the virus in the presence of amantidine. Castrucci and Kawaoka (16) have used such an amantidine-sensitive M gene based system to rescue the M gene of influenza A/PR/8/34 virus. Antibody-based rescue systems These systems depend on the binding or non-binding of the transfectant virus to a particular antibody (8, 17) Such antibody is a neutralising antibody which binds to influenza virus and impairs its growth in tissue culture The helper virus may, for example, carry a gene which encodes an influenza surface protein which displays the antibody epitope This system can therefore be used to select for transfectant virus which does not carry such a gene, but which of course is viable This type of rescue system thus allows the rescue of a gene encoding an influenza surface protein The gene to be rescued is transfected into cells infected with the helper virus The virus with the transfected gene is selected by growing the virus in the presence of the antibody Such a system was used by Enami and Palese (8) to rescue a transfected synthetic HA segment NP gene specific rescue system Li and coworkers (11) reported a reverse genetics system for the rescue of the influenza A virus nucleoprotein gene In this system, a temperature-sensistive (ts) mutant ts56 is used as a helper virus RNA complexes are reconstituted in vivo as described before (8) and are then introduced by electroporation into ts56 helper virus infected cells Transfectant viruses with a rescued NP-encoding vRNA segment are selected at the non-permissive temperature by plaqueing on MDBK cells Influenza B virus rescue system Barclay and Palese (18) have additionally described the rescue of HA genes in an influenza B virus The preparation of an attenuated influenza virus of the invention may alternatively be achieved using the expression vector-based influenza gene rescue strategy developed by Pleschka et al (19) In contrast to the RNP transfection system referred to above, this eliminates the need for purification of the viral NP and polymerase proteins which is required for in vitro reconstitution of RNP complexes Expression vectors are co-transfected into host cells which will provide the NP and P proteins (l e PB1, PB2 and PA) and also a nucleic acid of the invention In this case, RNP complexes of the invention are formed intracellularly The cells may then be infected with an influenza helper virus as previously described to select for the required attenuated influenza virus . An RNA complex of the invention may also be rescued in host cells into a viable attenuated virus by transfecting into the host cells additional complementing RNA complexes thereby eliminating the need for a helper virus This may be achieved in accordance with the general rescue strategy for influenza virus genes more recently described by Enami (20) This strategy involves purifying RNPs from an appropriate influenza virus and treating the RNPs in vitro with RNase H in the presence of a cDNA which hybridizes to the influenza virus gene to be rescued. In this way specific digestion of that gene by the RNase H is achieved The gene depleted RNPs are then co-transfected into cells with the RNP-complex containing the nucleic acid of the invention The cells are then overlaid with agar and transfectant attenuated viruses obtained by direct plaque formation This strategy, unlike the above described helper virus-based gene rescue strategies, can be applied to any influenza gene from any influenza virus. It can thus be applied to obtain an attenuated virus or nuclec acid of the invention of any influenza type. Helper-independent methods of viral rescue may also be used Generally such methods are based on cells capable of expressing the complete genomic vRNA segments of an influenza virus, or the corresponding cRNAs. Typically such cells are capable of providing a nucleoprotein and RNA dependent RNA polymerase whereby RNP complexes containing the genomic vRNA segments can be formed and viral particles can be assembled with the cells. Suitable systems are described in (27) and (28). From the discussion of the properties of the virus of the invention above it will be appreciated that the virus of the invention is suited for use in immunisation. Thus, in yet another aspect, the present invention provides a vaccine comprising a virus of the invention. Particularly preferred are such vaccines wherein the virus acts as a combined vaccinating agent against more than one pathogenic agent, e.g. the wild-type form of the virus of the invention and a second pathogenic agent other than the wild-type form of the virus of the invention Such vaccines may be formulated and administered in accordance with known methods for this purpose. Thus in a still further aspect, the present invention provides a method of stimulating an immune response against a virus, e g an influenza virus, either alone or together with stimulation of an immune response against one or more further pathogenic agents, which comprises administering in an immunising mode a virus of the invention capable of inducing said immune response(s) In the case of influenza intranasal immunisation with virus of the invention may, for example, be preferred Such immunisation may be carried out as illustrated by the immunisation studies with recombinant influenza viruses expressing an HIV-epitope reported by Muster et al (2) and Ferko et al (21) A suitable immunisation dose may be, for example, in the range of 10 3 -10 9 pfu Booster immunisations may be given following an initial immunisation with a virus having the same functional characteristics, but of a different subtype or type Methods for incorporating heterologous coding sequences into an influenza virus have previously been described, for example, in Published International Application WO91/03552 (Palese et al ) and are also reviewed by Muster and Garcia-Sastre in Textbook of Influenza 1998 (12) The heterologous coding sequence may be on the nucleic acid of the invention or on a different genomic segment It may be carried by an additional nucleic acid segment also incorporating a gene for an influenza viral protein to provide selection pressure It has previously been reported, for example, that an influenza virus can be constructed carrying at least 9 different vRNA segments ( 14) Use of attenuated recombinant influenza viruses of the invention as vectors to express foreign antigens for vaccinating purposes is an attractive therapeutic strategy since 1 Antibodies to the different subtypes show little cross-reactivity One drawback with the use of a virus as a vaccine is that an immune response will be produced to the virus It is often desired that one or more booster immunisations comprising the same antigen are given after the initial immunisation However, the immune response to the virus reduces the effectiveness of subsequent immunisations with the same virus Since antibodies to different influenza subtypes show little cross-reactivity, subsequent immunisations with an influenza virus of a different subtype but which expresses the same antigen should overcome this effect 2 Influenza viruses have been shown to induce strong cellular and humoral responses 3 Influenza viruses have been shown to induce strong mucosal responses Intranasal immunisation with influenza virus has been shown to induce long lasting responses in genital and intestinal mucosa 4 Influenza viruses are non-integrating and non-oncogemc 5 As previously noted above, attenuated influenza viruses of the invention can be anticipated to be attenuation stable A recombinant virus of the invention may be administered directly or used to infect cells ex vivo which are then administered to a patient Thus, in still further aspects, the present invention provides a pharmaceutical composition comprising a recombinant virus of the invention in combination with a pharmaceutically acceptable carrier or diluent for delivery of a heterologous coding sequence to target cells It also provides ex vivo cells infected by a virus of the invention and such cells hosting a virus of the invention formulated for administration with a pharmaceutically acceptable carrier or diluent In yet another aspect, the present invention provides a method of delivering a heterologous coding sequence to cells which comprises infecting said cells with a virus of the invention carrying said sequence Viruses of the invention may also find use as a helper virus to rescue genes which can substitute for the gene(s) affected by the attenuating mutatιon(s) to provide viruses showing increased growth on a selected cell type For this purpose, an attenuated virus will preferably be chosen which exhibits at least about a 3-4 log, preferably at least about a 5 log, reduction in growth compared to the corresponding wild-type virus on one or more cell types Thus, in yet another embodiment, the present invention provides use of a virus of the invention as a helper virus to rescue nucleic acid in cells, wherein viruses produced containing said segment are selected on the basis of increased growth compared with the helper virus on cells of a selected type For example, an influenza A virus of the invention having an attenuating poly U track replacement in NA-encoding vRNA may be usefully employed to rescue an NA-encoding vRNA or functional modification thereof derived from a second mfluenza A virus A typical protocol for this purpose will compπse the steps of 1 infecting cells with the helper virus, 2 transfection of an RNP complex containing the gene(s) to be rescued into the helper virus infected cells, and 3 selection of rescued viruses, either on the same cell type or a different cell type on which the helper virus shows increased attenuation The cell type in step 3 will be chosen such that only viruses which have acquired the transfected gene(s) are expected to grow to high titre Cultured cells which may prove useful in the selection of attenuated viruses of the invention m vitro include one or more of MDBK cells, Madin-Darby canine kidney (MDCK) cells and Vero (African green monkey kidney) cells A virus of the invention which is an influenza A/WSN/33 virus is particularly favoured as a helper virus for use to rescue NA genes originating from other influenza viruses of the A-type In this case, MDBK cells may, for example, be initially infected with such a helper virus and Vero cells preferably used for selection of viruses carrying an NA gene containing vRNA without an attenuating mutation Influenza A/WSN/33 is known to exhibit in mice neurovirulence associated with the surface antigen NA For this reason attenuated modified versions of that virus are not regarded as suitable for direct vaccine use However, when used as a helper virus as above, NA vRNAs may be obtained for site-directed mutagenesis to construct alternative attenuated influenza A viruses according to the invention more suitable for therapeutic, e g vaccine, use The invention is further illustrated by the accompanying drawings in which Figure 1 shows a model of vRNA with the wild-type conserved terminal sequences The proposed RNA hook model of the vRNA template is shown The U 6 track (the polyadenylation site) is shown in bold Figure 2 shows the effects of mutations of the U 6 track on CAT expression Human 293 kidney cells were tranfected with 4 protein expression plasmids (pGT-h- PB 1, pGT-h-PB2, pGT-h-PA and pGT-h-NP) and pPOL-I-CAT-RT with a wild-type polyadenylation signal (lanes 1 to 4), an U 6 - A < ; mutation (A^, lanes 5 and 6), or a U 6 → UCUACG mutation (RS, lanes 7 and 8) The CAT activities of the cell lysates were analyzed as described in Materials and Methods Dilution factors of the cell lysates are indicated Lane 9, mock transfection (C) Figure 3 shows that poly(U)-taιled NA mRNA is synthesized by the A 6 transfectant virus (A) RT-PCR assays Total RNA from cells infected with the wild- type virus (WT, lanes 2, 5 and 8) or the A 6 mutant (A 6 , lane 3, 5 and 9) was tested by RT-PCR reactions for vRNA (lanes 2 and 3), poly(U)-taιled NA mRNA (lanes 5 and 6) and poly(A)-taιled NA mRNA (lanes 8 and 9) RT-PCR products were analyzed on 8% native acrylamide gels The high molecular weight bands near the wells are non-specific PCR products Lanes 1, 4 and 7 are DNA markers (M) (B) Poly(U) sequence (n=84) of a cDNA clone derived from poly(U)-taιled NA mRNA The influenza virus mRNA sequence is indicated Figure 4 shows that the A 6 mutant is attenuated due to the reduction of NA expression (A) Growth curves of transfectant viruses on MDBK cells Cells were infected with the wild-type virus (WT) or the Aβ mutant (A ) at 0 01 MOI Infectious particles released into the media at the indicated time points were titrated by plaque assay in MDBK cells (B) NA activities of wild-type virus (WT) and the A 6 mutant (A t ) NA activity was expressed as nanomoles of 4-methylumbellιferone released per mm per microgram of viral protein (C) NA protein expression in infected cells Cells infected with A^ mutant (panel a and b), wild-type virus (panels c and d) and mock- infected cells (panels e and f) were tested for NA protein expression NA protein expression was visualized by fluorescence microscopy using of FITC-labelled antibody Cells were mounted in antibleach medium containing 4',6-dιamιdιno-2- phenyhndole (DAPI) for DNA staining The second column of the panels is the merged image of NA protein expression and cell nuclei Note that not all cells were infected with virus Figure 5 shows a pπmer extension assay for NA-specific vRNA (A) NA- specific vRNA levels in cells infected with the A^ mutant (Ag) and the wild-type virus (WT) Total RNAs from infected cells were isolated at the indicated time points p l The expected products for NA (259 nt) and NS (196 nt) vRNA are indicated (B) NA-specific vRNA levels in purified A^ mutant (A 6 ) and wild-type virus (WT) The expected products for NA (259 nt) and NS (196 nt) vRNA are indicated (C) NA vRNA to NS vRNA ratio in cells infected with the A^ mutant (A^) or wild-type virus (WT) Figure 6 shows a pπmer extension assay for NA-specific cRNA and mRNA (A) NA-specific cRNA and mRNA levels in cells infected with the A^ mutant (A ) and the wild-type virus (WT) Total RNA from infected cells was isolated at the indicated time points p I The expected products for NA cRNA (142 nt), NA mRNA (152-157 nt), HA cRNA (94 nt) and HA mRNA (104-109 nt) are indicated Since influenza virus mRNAs are initiated by capped RNA primers, which are heterogeneous in size, pπmer extension products of the mRNA are expected to produce a broad band which is 10-15 nt longer than products of cRNA (B) NA cRNA to HA cRNA ratio in cells infected with the A 6 mutant (Ag) or the wild-type virus (WT) (C) NA mRNA to HA mRNA ratio in cells infected the A 6 mutant (Ag) or the wild-type virus (WT) Figure 7 shows that poly(U)-taιled NA mRNA is predominantly localized in the nucleus Cells infected with the A 6 mutant (panels A-C and J-L), wild-type (panels D-F and M-O) virus and mock-infected cells (panels, G-I and P-R) were hybridized with NA mRNA-specific (panels A-I) or poly(U)-taιled NA mRNA- specific (panels J-R) probes Nuclei of cells were stained with D API (first column) The distribution of corresponding probe was visualized by fluorescence microscope (FITC, second column) The third column (Merge) is the merged image of the first and second columns Note that not all the cells were infected with virus The following examples also illustrate the invention Example 1 The effect on expression of replacing the poly U track of influenza virus Replacing the U-track of influenza virus (Fig 1) with an A-track in a model vRNA template resulted in synthesis of poly(U)-taιled mRNA both in vitro and in vivo To test whether a poly(U)-taιled mRNA could be used for gene expression, we used a plasmid-based chloramphemcol acetyltransferase (CAT) reporter system A CAT vRNA expression plasmid, pPOLI-CAT-RT (19), was transfected into human 293 kidney cells to synthesize a vRNA- ke template containing a CAT gene in negative oπentation, flanked by the 5' and 3' non-coding regions of segment 8 of influenza A/WSN/33 virus Four protein expression plasmids which encode viral PB1, PB2, PA and NP proteins were also cotransfected into the cell for the replication and transcription of the CAT vRNA template To synthesize poly(U)- tailed mRNA, the polyadenylation site (U 6 track) in the 5' noncoding region of the CAT vRNA template was mutated into an A^ track The presence of poly(U) sequences at the 3' end of mRNAs transcribed from this mutant template has been rigorously demonstrated elsewhere (1). When cells were transfected with a wild-type CAT vRNA expression plasmid, strong CAT activity was detected (Fig 2, lanes 1 to 4). However, when the U 6 — ϊAβ construct (see above) was transfected into the cells, only low (3 ±1.5% of the wild type) but significant CAT activity was detected (Fig 2, compare lanes 5 and 6 with lanes 1 to 4). By contrast, cells transfected with a control plasmid which contained a U 6 → UCUACG "random" mutation had no detectable CAT activity (Fig 2, lanes 7 and 8). These results confirm that a homopolymeric-track near the 5' end of vRNA was required for pausing of the polymerase, polymerase slippage and synthesis of a homopolymeric tail. Since no gene expression was detected when the U 6 track was mutated into a "random" sequence (Fig 2, lanes 7 and 8), these results also demonstrated that a homopolymeric track (either U 6 or A 6 ) is essential for gene expression. Example 2 Rescue of an influenza virus encoding an NA-specific mRNA with a polv(U tail Since the poly(U)-tailed mRNA transcribed from the CAT vRNA was translated, though at low efficiency, it was of interest to test whether we could rescue a transfectant influenza virus which could synthesize poly(U)-tailed mRNA. We decided to replace the polyadenylation signal (U 6 ) with an A 6 sequence in the vRNA of the NA segment, partly because of the availability of an efficient rescue system for this gene segment (7) and partly because influenza virus is known to tolerate severe reduction in NA protein levels. To construct a transfectant virus with an A-track (hereafter called A 6 mutant) in the polyadenylation site of the NA segment, a synthetic NA vRNA containing a j— »A <5 mutation in its 5' non-coding region was first reconstituted into ribonucleoproteins (RNPs). The reconstituted RNPs were then tranfected into cells infected with A/WSN HK helper virus (8). In three independent transfections, both wild-type and Ag mutant viruses were rescued. However, when the U-track was mutated into a random sequence (UCUACG), no transfectant virus could be rescued. The transfectant viruses were plaque purified three times and a single plaque of each virus was used for further analysis. To confirm the presence of the U 6 →A 6 mutation in the NA vRNA of the A 6 mutant, vRNA from purified virus was isolated, amplified by RT-PCR, cloned, and sequenced Apart from the introduced U 6 — Ae mutation, no other mutation was detected in the 5' and 3' non-coding regions of this segment (data not shown) other than a mutation of G→C at residue 195 (shown in Fig 3B) This additional mutation was inadvertently introduced in the mutagenesis protocol for generating the U 6 -»A 6 mutant NA plasmid prior to reconstitution of RNP' s This additional mutation in the 5' noncoding non-conserved region of the NA segment is not expected to contribute to the properties of the U 6 →A 6 mutant, as demonstrated in previous studies (see construct NA5D in (29)) The U 6 — »A(; mutation could be detected even after ten passages of the Ag mutant on MDBK cells (data not shown), indicating that the U 6 →A 6 mutation was stable at least over 10 passages Example 3 PolvCUVtailed NA mRNA is detected in cells infected with the A_ mutant To confirm that the U 6 — »A < ; mutation in the NA vRNA resulted in the synthesis of poly(U)-taιled NA mRNA, we isolated total RNA from cells infected with the wild-type virus or the A 6 mutant Total RNA was then tested by an RT-PCR assay which is specific for the detection of either poly(A)-taιled or poly(U)-taιled mRNA (22) In reverse transcription reactions, 5'-GC-clamped T 20 and 5'-GC- clamped A 20 primers were used to detected poly(A)-taιled and poly(U)-taιled mRNA, respectively The resultant positive signal appears as a characteristic smear as described before (22) As shown in Fig 3A, poly(U)-taιled NA mRNA was detected in the total RNA isolated from cells infected with the A <5 mutant (lane 6), but not in that isolated from cells infected with the wild-type virus (lane 5) By contrast, poly(A)-taιled NA mRNA could only be detected in RNA from cells infected with the wild-type virus (lane 8), but not in the RNA from cells infected with the Ae mutant (lane 9) These results showed that poly(U)-taιled NA mRNA was specifically synthesized in cells infected with the A 6 mutant and it was not polyadenylated Lanes 2 and 3 in Fig 3A show RT-PCR products corresponding to the 5' end of NA vRNA isolated from cells infected with the wild type and the A <5 mutant, respectively The strong signals comigrating with the 134 nucleotide (nt) DNA marker indicate that cells used for RNA isolation were, as expected, infected with viruses. The RT-PCR products from poly(U)-tailed mRNAs (lane 6) were then cloned and sequenced (see Materials and Methods). Nine independent clones were found to contain poly(U) sequences in the range of 40 to 127 nucleotides. Fig. 3B shows one example with a poly(U) tail of 84 U residues. Example 4 The Annuitant is attenuated due to the reduction of NA protein expression The An mutant consistently produced small plaques when grown on Madin- Darby bovine kidney (MDBK) cells (data not shown), suggesting that this mutant was attenuated. To characterize the growth properties of the A 6 mutant in more detail, confluent MDBK cells were infected at multiplicity of infection (moi) of 0.01 and the number of infectious viral particles released into the medium was assayed by plaque assay on MDBK cells. As predicted from the plaque size, the A 6 mutant was attenuated. The maximum plaque titre of the A 6 mutant was about 1 log lower than that of the wild type (Fig. 4A). The Ag mutant was also tested on Madin-Darby canine kidney (MDCK) cells and there was, again, about a 1 log reduction in maximum plaque titre compared to the wild-type virus (data not shown). In the light of the CAT reporter gene study (see above, Fig. 2), the mostly likely explanation for the attenuation of the A 6 mutant was the reduction of NA protein expression. To test this possibility, a spectrofluorometric assay (see Materials and Methods) was used to analyse the NA activity associated with the purified virus. The NA activity of the A 6 mutant was about 8% of the wild type (Fig. 4B). We then used a monoclonal anti-NA antibody to show that the reduction of NA protein in virions was due to the low expression of the NA protein in infected cells. As shown in Fig. 4C, NA was highly expressed in the cytoplasm of the cells infected with the wild-type virus (panel d). By contrast, cells infected with the Ag mutant expressed significantly less NA protein (panel b). Although the results of the immunofluorescence assay are not quantitative, they are in agreement with the results in Fig. 4B showing that reduced amounts of NA were incorporated into virions. In addition, these results suggest that the attenuation of the A mutant was due to the reduction of the NA protein expression in cells infected with the A mutant. Example 5 Levels of the NA vRNA and mRNA but not cRNA are specifically reduced The above results showed that the NA protein expression in cells infected with the A 6 mutant was severely reduced Such reduction could be due to low levels of poly(U)-taιled mRNA synthesis in infected cells To test this hypothesis, total RNA was isolated from infected cells at different time points and the amounts of NA-specific vRNA, cRNA and mRNA were quantified by primer extension assays In the primer extension assay for NA vRNA analysis, the NS vRNA was used as an internal control As shown in Fig 5A, at every time point tested, NA vRNA levels in cells infected with the A^ mutant were lower than those in cells infected with the wild-type virus By contrast, the NS vRNA levels from cells infected with the A 6 mutant were similar to those of the wild type When the NA vRNA levels were normalized to the NS vRNA levels in infected cells, the steady state NA vRNA levels of the Aβ mutant were between 40-53 % of those of the wild type (Fig 5C) We also quantified the amount of NA vRNA in virions (Fig 5B) The levels of the NA vRNA in the transfectant virus (the An mutant) were about 60 % of that of the wild type (Fig 5B) Since both cRNA and mRNA are positive sense, the same NA- specific primer was used to analyze both these RNAs In these pπmer extension reactions, a haemagglutinin (HA)-specιfic primer was used as an internal control As shown in Fig 6A, cells infected with the wild-type virus had more NA mRNA then the NA cRNA By contrast, the NA mRNA signals in cells infected with the Aβ mutant were much weaker than NA cRNA signals These results suggested poly(U)- tailed mRNA was synthesized in a reduced level When the levels of the NA cRNA were normalized to the internal control (i e HA cRNA), the steady state cRNA levels of the A mutant were not statistically different from those of the wild type in a student t-test (from 3 independent experiments) (Fig 6B) By contrast, when we normalized the NA mRNA to the internal control (I e HA mRNA), the steady state mRNA levels of the A 6 mutant in infected cells were only about 40 to 50% of those of the wild type (Fig 6C) These results demonstrated that the NA mRNA, but not the NA cRNA of the Ag mutant was synthesized at reduced levels Example 6 PolvCUVtailed NA mRNA is predominantly localized in nucleus Although cells infected with the Ag mutant showed a reduction of the NA mRNA levels, such reduction could not fully explain the dramatic reduction of the NA activity of the A 6 mutant (8% of the wild type, Fig 4B) Since the influenza virus mRNAs are synthesized in the nucleus of infected cells, it was possible that the poly(U)-taιled NA mRNA was defective in nuclear export To address this question, we used fluorescent in situ hybridization to visualise the distribution of the poly(U)- tailed NA mRNA in infected cells (Fig 7) We first used a πboprobe which is specific for the positive sense NA RNAs (1 e detects both mRNA and cRNA) (Fig 7, panels A to I) Since cRNAs are synthesized in low amounts compared to mRNAs during infection and they remain in the nucleus throughout viral infection, one may assume that any positive signal in the cytoplasm represents mRNAs, while a signal in the nucleus represents predominantly mRNA, although cRNA might partly contribute to this signal As shown in Fig 7 (panels D to F), cells infected with the wild-type virus showed strong signals in the cytoplasm These results showed that poly(A)-tailed mRNAs were transported from the nucleus to the cytoplasm, as expected By contrast, in cells infected with the A 6 mutant, positive sense NA RNAs could only be detected in the nucleus (Fig 7, panels A to C), suggesting that poly(U)-mRNAs have a defect in nuclear transport and remain mainly in the nucleus No signal was detected in mock infection (Fig 7, panels G to I) To confirm that poly(U)-tailed NA mRNAs remained mainly in the nucleus after being synthesized, we used a riboprobe specific for the poly(U)-tailed NA mRNA, but not for NA cRNA, in the in situ hybridization As expected, no poly(U)- tailed NA mRNA was detected in cells infected with wild-type virus (Fig 7, panels M to O) or in mock infections (Fig 7, panels P to R) By contrast, poly(U)-taιled NA mRNAs were detected in cells infected with the A 6 mutant (Fig 7, panels J to L) More importantly, the poly(U)-tailed NA mRNA was predominantly detected in nuclei of infected cells (Fig 7, panels J to L) In summary, these results demonstrate that the poly(U)-tailed mRNA remains predominantly in the nucleus after synthesis, which strongly suggests that the poly(U)-taιled mRNA is defective in nuclear export Example 7 Pathogenicity and efficacy of the A6 mutant The pathogenicity of and the protection provided by the A6 mutant was determined by using Balb/C mice. The mice were challenged with varying titres of wild- 5 type or mutant virus to study pathogenicity and then observed for signs of pneumonia. To study the protective effect of the mutant virus mice infected with mutant influenza virus were subsequently challenged by infection with wild type influenza virus and monitored for illness. The mouse influenza challenge model is an established system for the study of influenza infection and has historically been used to determine the efficacy of 10 vaccines or antiviral compounds against influenza. 42 female Balb/C mice (Charles River UK Ltd.) which were 6 to 12 weeks old and randomised by litter were used in the study. The mice were divided into 7 groups of 6 mice and were all electronically tagged to allow identification of each individual within a group. On day 0 all mice were anaesthetised using halothane/oxygen and infected with 15 50μl of influenza virus intranasally, the individual weight of each mouse was recorded. The seven groups of mice were administered with mutant or wild-type virus as shown in Table 1. All mice were individually observed daily for clinical symptoms and weighed. Any mice showing advanced symptoms of pneumonia or any mice losing 20% or more of their body weight were euthanased following a Home Office schedule 1 procedure. 20 General health scoring of all mice was on a scale of 0 (full health) to 8. Any mice scored over a 7 were euthanased, and scored as an 8 for the rest of the study. The final weight of euthanased mice was included in the group mean for the remaining days of the study. All mice were observed for a period of 21 days post infection. Any surviving mice from the A/WSN/33 wild type groups were euthanased following a Home Office schedule 1 25 procedure. On Day 21 -post infection, all remaining mice (including the uninfected control group) received a second infection of 50μl of A/WSN/33 wild type. All mice were observed daily for clinical symptoms. The same endpoints for euthanasia were used as before. After 10 days post second infection, the remaining mice were sacrificed. Table 2 shows the results of the pathogenicity study. Severe health effects were observed 30 in mice infected with wild type virus on days or 2 or 3 onwards and most had to be euthanased. In contrast only slight effects were noticed on days 7 and 8 in a few mice of the group infected with the highest dose of mutant virus. No ill effects were observed at lower doses. Table 3 shows the results of the protection study. The health and weight figures of challenged with wild type virus after initial infection with the poly U modified virus were significantly better than for the control group. Severe health effects and weight loss were observed in unprotected control group within 2 days of challenge. However, the health effects and weight loss were much less in mice which had been previously been infected with mutant virus at any dose, with almost no effects in the highest dose group. Thus the mutant virus provided significant protection against a dose of wild type virus that would normally be lethal. Discussion The polyadenylation site in influenza virus vRNA templates has been mapped to a track of uridine residues near the 5' end of the vRNA. Here, we engineered an influenza vims which contains a U 6 to A 6 mutation at the 5' end of the NA vRNA segment. As a consequence of the U 6 to Ag mutation, this novel transfectant virus synthesized NA mRNA with a poly(U)-tail instead of the usual poly(A) tail. It is not surprising that we did not detect any poly(A) sequence in the NA mRNA, since the poly(U)-tailed mRNA lacked the viral signal for polyadenylation. Moreover, the mRNA does not contain signals for the eukaryotic polyadenylation machinery. Thus, it is unlikely that any known host enzyme could add a poly(A) sequence to the poly(U)-tailed NA mRNA. Interestingly, low expression of NA was detected in cells infected with the A 6 mutant, indicating that poly(U)-tailed NA mRNA could be translated. The U 6 to A 6 mutation is surprisingly stable during viral passages; no reverse mutation in the Aβ track was detected even after 10 viral passages. By contrast, when the U 6 track was mutated into a random sequence (TCTACG), no virus was rescued, suggesting that a homopolymeric-track at the polyadenylation site was essential for mRNA synthesis. These results were confirmed by the CAT reporter assay (Fig. 2), in which a U6→ TCTACG mutant showed no CAT expression. The A^ mutant was attenuated in cell culture. When we analyzed the NA activity of the mutant virus, it was only about 8% of the wild type and this correlates with a reduced level of NA expression in cells infected with the A 6 mutant. NA is known to promote the release of viral particles from the cell surface by removal of terminal sialic acid from both the cell surface and virus glycoproteins, and thus promote viral spread. Therefore, the attenuation of the A 6 mutant was most likely due to the reduced levels of NA expression in cells. We detected reduced levels of poly(U)-tailed NA mRNA in infected cells, suggesting that the low NA expression could be due to the low levels of poly(U)- tailed NA mRNAs. Since model vRNA templates with either a U 6 or A 6 track could synthesize similar amounts of mRNAs in vitro (1), it was unlikely that the mutated NA vRNA of the A 6 mutant was a less efficient template for the synthesis of poly(U)-tailed mRNA. The observed reduction of poly(U)-tailed NA mRNA levels was more likely due to the reduction of the NA vRNA levels. When we analyzed the steady state levels of vRNAs in infected cells, there was a 50%> reduction of NA vRNA levels. It was shown that the nonconserved nucleotides at the 3' and 5' ends of vRNA play an important role in replication. It is possible that the U 6 to A 6 mutation, which resulted in changing the nonconserved sequences of cRNA and vRNA, could somehow down-regulate the replication process. However, the NA cRNA level of the A mutant was not affected by the mutation. In wild-type vims infection, vRNA can be transported to the cytoplasm for packaging into progeny virions or used as a template for transcription and replication. It is possible that, in the case of the A 6 mutant infection, NA vRNAs which are normally used for mRNA synthesis or transported to the cytoplasm are recruited to NA cRNA synthesis so as to maintain sufficient levels of NA cRNA templates for NA vRNA synthesis. The severe reduction of NA activity of the Aβ mutant vims (8% of that of the wild type) did not correlate with the reduced NA mRNA level in cells infected with the A mutant (50%> of that of the wild type). This indicates that the reduced level of poly(U)-tailed mRNA might not be the only factor that affects NA expression. From the results of in situ hybridization (Fig. 7), we observed different localization patterns of poly(A)- tailed and poly(U)-tailed NA mRNAs. Poly(A)-tailed NA mRNAs were mainly distributed in cytoplasm. By contrast, poly(U)-tailed NA mRNAs were found predominantly in the nucleus. Since protein synthesis occurs in the cytoplasm, a defect in the transport of poly(U)-tailed NA mRNAs from nucleus to cytoplasm would lead to limited amounts of mRNAs for protein expression. Hence, the severe reduction of NA protein expression in infected cells was most likely caused by the retention of poly(U)-tailed mRNAs in the nucleus. We were not able to detect NA mRNA in the cytoplasm of A^ mutant-infected cells (Fig. 7) indicating that poly(U)- tailed NA mRNA was present in the cytoplasm at levels below our detection limit On the other hand, the detection of NA protein in infected cells (Fig 4B) and in the A 6 mutant vims (Fig 4C) clearly demonstrated that a certain amount of poly(U)- tailed NA mRNAs was available for translation Thus it had to be transported (or diffused) into the cytoplasm We do not know whether replacing the poly(A) tail of the NA mRNA with a poly(U) tail affects translation efficiency However, knowing that the majority of the poly(U)-taιled mRNA remains in the nucleus, the significant level of NA protein expression (8%> of that of the wild type) in the A6 mutant-infected cells suggests that the poly(U)-taιled NA mRNA is a competent template for translation Non- polyadenylated influenza vims mRNAs are known to be translated under in vitro conditions Results from the present study also show that polyadenylation is not required for translation Furthermore, our results imply that other factors are involved in the control of viral translation Thus, the 5' untranslated region of the viral mRNA, the NS 1 protein and some cellular proteins are known to facilitate the translation of viral mRNAs Hence, the poly(A) tail of the influenza virus mRNA is not essential for translation and its most important function might be to direct influenza mRNA export from the nucleus to the cytoplasm Several influenza vims proteins have been shown to be involved in processes related to RNA transport For example, nucleoprotein and matrix protein 1 are known to bind to vRNA and facilitate its nuclear export Recently, NS2 (also known as NEP) was identified as having a similar function to the Rev protein of HIV- 1 in mediating viral RNP export However, these proteins seem to be restricted to mediating nuclear export of vRNA only The NSl protein appears to interact with the cellular 3'-end processing machinery and inhibits the nuclear export of cellular poly(A)-contaιnιng mRNAs However, new evidence suggests that these functions of NSl are dispensable for viral replication under certain conditions Since influenza virus mRNAs have a similar structure to cellular mRNAs [e g 5' cap and poly(A) tail], it would not be surpπsing if they utilized cellular mRNA transport system for nuclear export In eukaryotic cells, there is a growing body of evidence supporting the idea that maturation of cellular pre-mRNAs is a prerequisite for nuclear export In agreement with this idea, the addition of poly(A) tail was found to stimulate mRNA export For non-polyadenylated histone mRNAs, the generation of mature 3' end is also known to be required for nuclear export Here, in the absence of a characteristic signal of mature mRNA [e g poly(A) tail], cellular nuclear export factors might regard the poly(U)-taιled NA mRNA of the A^ mutant as a pre-mRNA and retain the poly(U)-taιled mRNA in the nucleus Since the synthesis of the poly(A) tail by the influenza virus RNA polymerase does not require the cellular cleavage/polyadenylation machinery, our results suggest that a poly(A) sequence itself is required for efficient mRNA export On the other hand, it is possible that the poly(U) tail, itself, is a signal for nuclear retention In eukaryotic cells, several cellular proteins that are associated with the mRNA in the nucleus are selectively removed prior to mRNA nuclear export, indicating that some of these cellular proteins might be involved in nuclear retention Interestingly, hnRNP C protein, a protein which is involved in mRNA nuclear retention, has been shown to have avid binding properties for a poly(U) sequence We speculate that hnRNP C protein, or perhaps other nuclear retention factors (cellular and viral), might specifically bind to the poly(U) sequence of the poly(U)- tailed mRNA and impede the export of poly(U)-taιled mRNA from the nucleus to the cytoplasm Materials and Methods Viruses. Influenza A/WSN/HK vims, a reassortant vims containing an NA segment from influenza A/HK/8/68 vims and all other segments from influenza A/WSN/33 vims, was grown in embryonic chicken eggs Influenza X-31 vims is a reassortant vims of influenza A/HK/8/68 vims and influenza A/PR/8/34 Plasmid transfection and CAT assay. Plasmids pGT-h-PB 1 , pGT-h-PB2, pGT-h-PA, pGT-h-NP, which express the influenza PB1, PB2, PA and NP proteins, respectively, and pPOLI-CAT-RT were generously provided by P Palese (1, 19) One μg of each plasmid was transfected into 293 cells with 25 μl of DOTAP transfection reagent (Boehπnger Mannheim) as instmcted by the manufacturer Mutated versions of the pPOLI-CAT-RT plasmid were made by an inverse PCR technique with Pfu DNA polymerase and the mutated sequences were confirmed by DNA sequencing At about 60 hours post-transfection, cell extracts were harvested and tested for CAT activity as described (23). 50 μl of undiluted or diluted cell extracts were incubated in 75 μl reaction mixtures containing 0.08 μCi [ C]chloramphenicol, 1 mMacetyl-CoAand250 mM Tris-HCl (pH 7.5). After incubation at 37°C for 2 hours, reaction products were extracted by ethyl acetate and then separated by thin-layer chromatography. Acetylated products were detected by autoradiography and analyzed in a phosphorimager. Preparation of influenza A virus RNP and RNP transfection. RNA polymerase and nucleoprotein were isolated from influenza A vims, strain X-31 , as described previously (25). Briefly, the vims was disrupted with Triton X-100, NP-40 and lysolecithin. RNP was separated by glycerol step gradient centrifugation. Fractions enriched in RNP were treated with micrococcal nuclease and then used, after the addition of EGTA, in RNP transfection. Plasmid pT3NAMl (5), which encodes the full-length wild-type NAvRNA segment of influenza A/WSN/33, was generously provided by P. Palese. Mutated versions of the plasmid were made by an inverse PCR technique with Pfit DNA polymerase and the mutated sequences were confirmed by DNA sequencing. RNP transfections were conducted as described (8). Briefly, 5pz/AI-linearized pT3NAM 1 was transcribed by T3 RNA polymerase at 37°C for 30 min in the presence of micrococcal nuclease-treated RNP. The reconstituted RNP complexes were transfected with DEAE- dextran into MDBK cells infected with influenza A/WSN/HK helper vims. After a one day incubation, medium from transfected cells was checked for the presence of transfectant viruses by plaque assay on MDBK cells. Virus Purification. Transfectant viruses were plaque purified three times in MDBK cells covered with agar overlay medium. Purified viruses were then grown in MDBK cells and purified through a 30%o sucrose cushion, followed by purification on a 30 to 60%) sucrose gradient. Sequencing of the 5' and 3' ends of the NA gene. cDNA clones of the 5' end of the NA segment from transfectant vimses were obtained by rapid amplification of 5' DNA ends (5' RACE). NA vRNA from the purified transfectant vimses was reverse transcribed by using a primer 5'-GGGTGTCCTTCGACCAAAAC-3' (complementary to nt 879-898 of the NA vRNA) and Superscript π reverse transcriptase (Gibco BRL). The reverse transcribed product was tailed with a poly(C) sequence at its 3' end by terminal deoxynucleotidyltransferase The poly(C)-taιled cDNAs were amplified by PCR with apnmer5'-TGGACTAGTGGGAGCATCAT-3' (complementary to nt 1280- 1299 of the NA vRNA) and a 5' RACE abridged anchor primer as instmcted by the manufacmrer ( ) (Gibco BRL) PCR products were then cloned into pGEM -T vector (Promega) and sequenced To synthesize cDNA of the 3' end sequence of the NA segment, vRNAs from purified vimses were first polyadenylated by poly(A) polymerase (Gibco BRL) The polyadenylated vRNA was reverse transcribed by using a primer 5'- GCGCTCTAGAATTCTTTTTTTTTTTTTTTTAGC-3' cDNAwas amplified by PCR with the primer for reverse transcription and a primer 5'- GTTGAGTCCTGCCCAGCAACAACT-3' corresponding to nt 1 197-1220 of the NA (R) vRNA PCR products were then cloned into pGEM -T and sequenced NA activity assay. The NA activity was determined as described before (25) Briefly, purified vimses (~ 3 μg) were incubated in 100 μl 150 mM phosphate buffer containing 1 mM CaCl 2 and 50 nmol of 2'-(4-methyl-umbellιferyl)-α-D-N-acetylneuramιnιc acid (MU-NANA) (Sigma) for 10 mm at 37°C Reactions were then stopped by adding 2 ml of 0 5 M glycine-NaOH (pH 10 4) and the released 4-methylumbellιferone was assayed by using a spectrofluoπmeter (Shimadzu, RF-540) A 0 1 mM solution of 4- methylumbelhferone (Sigma) was used as a standard control Immunofluorescence microscopy. MDBK cells grown on glass cover slides were washed with phosphate buffered saline (PB S) and then infected with vimses at about 0 5 moi Infected cells were harvested at 10 hr p i , washed twice in PBS and fixed in 4%> paraformaldehyde in PBS Fixed cells were permeabilised with 0 5% Tπton-X-100 in PB S for 15 mm, followed by two washes in PB S Cells were then incubated with a 100 times diluted mouse monoclonal anti-NA antibody (H17-L17-5, a generous gift from Walter Gerhard) overnight at 4° C After two washes m PB S with 0 01 % Tπton-X- 100, cells were incubated with a horse anti-mouse antibody conjugated with fluorescein (Vector, 1 200 dilution) for one hour at room temperature Samples were washed twice in PBS containing 0 01%) Tπton-X-100 and then mounted in antibleach medium containing 4',6-dιamιdιno-2-phenyhndole (DAP I) for DNA staining (Vector) Samples were examined on a Zeiss Axiophot microscope RT-PCR assays for mRNA and vRNA from infected cells. MDBK cells infected with vimses at an moi of 2 were harvested at 12 hr p I Total RNA was isolated with Tπzol (Gibco BRL) as instmcted by the manufacturer To detect the N A vRN A, about 1 5 μg total RNA was first reverse transcribed by 25 U Moloney muπne leukemia vims reverse transcπptase (M-MLV RT, Promega) at 42°C for 30 mm in the presence of an NA vRNA-specific primer 5'-GGGTGTCCTTCGACCAAAAC-3' (complementary to nt 879-898 of the NA vRNA) The reverse transcribed products were then amplified by Taq polymerase with primers 5'-TGGACTAGTGGGAGCATCAT-3' (complementary to nt 1280-1299 of the NA vRNA) and 5' ggactagtagtAGTAGAAAC AAGG-3 ' (underlined nt corresponding to the first 13 nt of the 5' end of NA vRNA) To detect the homopolymeric tails of NA mRNA, RT-PCR was performed as described before (22) About 1 5 μg total RNA was first reverse transcribed by 25 U M- MLV RT (Promega) at 42°C for 30 min in the presence of either a 5' GC-clamped T 20 primer [5'-GCCCCGGGATCCT 2 o-3', specific for poly(A)-taιled mRNA] or a 5' GC- clamped A 20 primer [5'-GCCCCGGGATCCA 2 o-3', specιficforpoly(U)-taιledmRNA] The reverse transcribed products were then amplified by Taq polymerase using 5'- TGGACTAGTGGGAGCATCAT-3' (complementary to nt 1280-1299 of the NA gene) and the corresponding primer specific for the homopolymeric tail All PCR products ( ) were then cloned into pGEM -T and sequenced Primer extension assay. Total RNA from cells infected with vimses at an moi of 2 was isolated with Tπzol (Gibco BRL) at the indicated time points Primer extension assays were performed as described before (25) About 0 2 μg of viral RNA or 5 μg of total RNA were reverse transcribed by 200 U Superscript (Gibco BRL) for 45 min at 42°C in the presence of the corresponding P-labelled primer Reactions were terminated by adding equal volume of formamide loading dye Products were then heated to 99°C for 2 min and analyzed on 5% polyacrylamιde-7 M urea gels To quantify the yield of the reverse transcribed products, gels were dried and analyzed in a Phosphoπmager To determine NA and NS vRNA levels, an NA vRNA-specific pπmer (5'- GTGGCAATAACTAATCGGTCA-3', complementary to nt 1 151 - 1 171 of NA vRNA) and a NS vRNA-specific primer (5'-GGGAACAATTAGGTCAGAAGT-3', complementary to nt 695-715 of NS vRNA) were used in the primer extension assay An NA cRNA/mRNA-specific primer (5'-GTTGAGTCCTGCCCAGCAACAACT-3', corresponding to nt 142-122 of the NA vRNA) and an HA cRNA/mRNA-specific primer (5'-CATATTGTGTCTGCATCTGTAGCT-3' ; corresponding to nt 94-71 of the HA vRNA) were used to determine mRNA and cRNA levels of NA and HA, respectively In situ hybridization. MDBK cells grown on glass cover slips were washed with PBS and then infected with vimses at an moi of 0 5 Infected cells were harvested at 8 hour p l , washed twice with PBS and fixed in 4% paraformaldehyde in PBS The fixed cells were then permeabhzed by PBS containing 0 5%o Triton X-100 for 15 min at room temperature Cells were then washed twice in PBS followed by washing in 2xSSC (IX SSC = 0 15 M NaCl, 0 015 M sodium citrate) twice Samples were hybridized in 20 μl of hybridization buffer (50%> formamide, 2X SSC, 10% dextran sulphate, lmg/mlof E coli tRNA) containing about 100 ng of πboprobe at 37°C for overnight After hybridization, cells were washed twice in hybridization buffer at 37°C, followed by successive washings for 15 min with 2X SSC, IX SSC, 0 5X SSC and 0 2X SSC at room temperature Samples were then incubated in 4X SSC containing 1 μg/ml anti- digoxigenin-fluorescein antibody (Boehπnger Mannheim) for 1 hour at room temperature After the incubation, samples were washed with 4X SSC containing 0 01 %> Triton X-100 three times and mounted in antib leach medium containing D API for DNA staining (Vector) Samples were examined by a Zeiss Axiophot microscope For NA cRNA and NA mRNA detection, a πboprobe (corresponding to nt 1 to 299 of the NA vRNA) was prepared by T3 RNA polymerase transcription of BamHl- lineaπzed pT3NAMl For poly(U) tail mRNA detection, a plasmid which contains a poly(A) sequence and part of 3' end of the NA gene was constructed The transcription product from this plasmid contained a sequence of 86 A residues [specific for the poly(U) tail] and the last 21 NA-specific residues of NA mRNA Both πboprobes were labelled with digoxigenin-UTP (Boehπnger Mannheim) during in vitro transcriptions References Poon, L. L. M., D. C. Pritlove, E. Fodor, and G. G. Brownlee. 1999 Direct evidence that the poly(A) tail of influenza A vims mRNA is synthesis by reiterative copying of a U-track in the vRNA template J Virol 73:3473-3476 Muster TΛ, Ferko B., Klima, A. et al. 1995 Mucosal model of immunisation against human immunodeficiency vims type 1 with a chimeric influenza vims J Virol 69, 6678-86 Li, S., Polords, V., Isobe, H. et al. 1993 Chimeric influenza vims induces neutralising antibodies and cytotoxic T cells against human immunodeficiency vims type 1 J Virol 67, 6659-66 Rodrigues, M., Li, S., Murata, K., Rodrigues D. 1994 Influenza and vaccinia vimses expressing malaria CD8+ T and B cell epitopes J Immunol 153, 4636-48 Garcia-Sastre, A., T. Muster, W. S. Barclay, N. Percy, and P. Palese. 1994 Use of a mammalian internal πbosomal entry site element for expression of a foreign protein by a transfectant influenza vims J Virol 68 6254-6261 Percy, N., Barclay, W. S., Garcia-Sastre, A. and Palese, P. 1994 Expression of a foreign protein by influenza A vims J Virol 68, 4486-92 Enami, M., W. Luytjes, M. Krystal, and P. Palese. 1990 Introduction of site specific mutations into the genome of influenza vims Proc Natl Acad Sci USA 87 3802-3805 Enami, M., and P. Palese. 1991 High-efficiency formation of influenza vims transfectants J Virol 65 2711-2713 Garcia-Sastre, A. and Palese, P. 1993 Genetic manipulation of negative-strand RNA vims genomes Ann Rev Microbiol 47, 765-90 Luytjes, W., M. Krystal, M. Enami, J. D. Parvin, and P. Palese. 1989 Amplification, expression, and packaging of a foreign gene by influenza vims Cell 59 1 107-1 1 13 Li, S., Xu, M. and Coelingh, K. 1995 Electroporation of πbonucleoprotein complexes for rescue of the nucleoprotein and matrix genes Vims Res 37, 153- 161 Muster, T. and Garcia-Sastre, M. June 1998 Textbook of Influenza, Blackwell Science Ch 9, p 93-106, Genetic Manipulation of Influenza Vimses Liu, C. and Air, G. M. 1993 Selection and characterisation of a neuraminidase- minus mutant of influenza vims and its rescue by cloned neuraminidase genes Virology 194, 403-7 14 Enami, M., Sharma, G., Benham, G. and Palese, P. 1991. An influenza vims containing nine different RNA segments. Virology 185, 291-8 15 Subbarao, E. K., Park, E.J., Lawson, CM., Chen, A.Y. and Murphy, B.R. 1995 Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant vims can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A vims vaccine J Virol. 69, 5969-77 16 Castrucci M. R. and Kawaoka, Y. 1995 Reverse genetics system for generation of an influenza A vims mutant containing a deletion of the carboxyl-terminal residue of M2 protein. J Virol. 69, 2725-8. 17. Horimoto, T. and Kawaoka, Y. 1994. Reverse genetics provides direct evidence for a correlation of haemagglutinin cleavability and virulence of an avian influenza A vims. J. Virol. 68, 3120-3128. 18. Barclay, W.S. and Palese, P. 1995. Influenza B vimses with site-specific mutations introduced into the NA gene. J. Virol. 76, 3211-5. 19. Pleschka, S., Jaskunas, R., Engelhardt, O.G., Zurcher, T., Palese P. and Garcia-Sastre, A. 1996. A plasmid-based reverse genetics system for influenza A vims. J. Virol. 70, 4188-92. 20. Enami, M. 1997. Improved technique to genetically manipulate influenza vims. InFrontiers ofRNA Vims Research p.19, The Oji International Seminar in Natural Science, Kyoto, Japan 1997. 21. Ferko, B., Egorov, A. et al. 1997. Influenza vims as a vector for mucosal immunisation. In Frontiers of RNA Vims Research, p.18. The Oji International Seminar in Natural Science, Kyoto, Japan. 22. Pritlove, D. C., L. L. M. Poon, E. Fodor, J. Sharps, and G. G. Brownlee. 1998. Polyadenylation of influenza vims mRNA transcribed in vitro from model virion RNA templates: requirement for 5' conserved sequences. J. Virol. 72: 1280-1286. 23. Gorman, M., L. F. Moffat, and B. H. Howard. 1977 Recombinant genomes which express chloramphenicol acetyl-transferase in mammalian cell. Moi. Cell. Biol. 2:1044-1051. 24. Seong, B. L., and G. G. Brownlee. 1992. A new method for reconstituting influenza polymerase and RNA in vitro: a study of the promoter elements for cRNA and vRNA synthesis in vitro and viral rescue in vivo. Virology 186:247-260. 25. Fodor, E., P. Palese, G. G. Brownlee, and A. Garcia-Sastre. 1998 Attenuation of influenza A vims mRNA levels by promoter mutations. J Virol. 72:6283-6290. 26. Egorov, A. et al. 1998. Transfectant influenza A vimses with long deletions in the NS 1 protein grow efficiently in Vero cells J. Virol. 72:6437-6441 Fodor et al. 1999 Rescue of Influenza A vims from Recombinant DNA J Virol 73 9679-9682 Neumann et al. 1999 Generation of influenza A vimses entirely from cloned cDNAs Proc Natl Acad Sci USA 96 9345-9350 Zeng et al. 1996 Nonconserved nucleotides at the 3 1 and 5' ends of an influenza A vims RNA play an important role in viral replication Virology 217 242-251 Table 1. Immunisation schedule Table 2. Virulence of mutant virus Weight - mean percentage starting weight (day 0 is 100 for all groups) Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Group 1 wild type 1x10 Λ 6 pfu 103 9 96 5 92 1 89 8 89 4 89 6 89 5 88 7 88 6 88 5 88 7 88 8 88 7 88 5 88 9 89 6 88 6 89 6 89 8 89 7 90 5 Group 2 wild type 3x10 Λ 4 pfu 103 9 93 9 86 3 80 8 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 78 5 Gioup 3 wild type 1X10 Λ 3 pfu 103 6 101 0 92 7 88 3 84 1 82 3 79 9 79 7 80 5 80 6 81 9 82 2 82 7 82 3 82 7 83 2 83 0 83 2 84 0 83 8 84 4 Gioup 4 mutant 1x10 Λ 6 pfu 103 0 99 7 103 0 103 9 103 0 103 8 103 0 102 7 103 0 104 1 102 5 103 2 102 3 102 4 103 0 103 4 102 3 104 1 105 8 104 4 105 8 3 Group 5 mutant 3x10 Λ 4 pfu 102 6 104 9 104 4 105 9 105 1 104 5 103 6 103 7 106 2 105 1 106 2 107 9 107 7 108 2 109 3 108 8 107 6 110 4 112 1 109 5 110 3 Gioup 6 mutant 1X10 Λ 3 pfu 100 5 101 6 102 9 103 7 103 0 103 9 103 9 103 5 103 1 104 0 102 6 103 4 104 3 104 9 102 8 104 8 103 9 105 7 107 7 105 1 106 3 3 Group 7 PBS 104 9 106 0 106 2 107 3 106 4 106 5 105 6 104 9 105 5 105 6 104 7 107 8 106 9 106 6 106 8 108 2 107 5 107 6 108 6 106 9 107 8 I Health Score - mean per group (day 0 is 0.00 for all groups) Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Group 1 wild type 1x10 Λ 6 pfu 000 283 483 617 550 533 567 567 533 533 533 533 533 533 533 533 533 533 533 533 533 Group 2 wild type 3x10 Λ 4 pfu 000 317 483 650 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 800 Group 3 wild type 1X10 Λ 3 pfu 000 000 417 450 600 650 700 750 700 700 667 667 667 667 667 667 667 667 667 667 667 Group 4 mutant 1x10 Λ 6 pfu 000 000 000 000 000 000 100 067 000 000 000 000 000 000 000 000 000 000 000 000 000 Gioup 5 mutant 3x10 Λ 4 pfu 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 Group 6 mutant 1X10 Λ 3 pfu 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 Gioup 7 PBS 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 000 Table 3. Protection study Weight - mean percentage starting weight Challenge 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Gioup 4 mutant wild type 1x lO Λ 6 100 97 6 98 6 98 2 99 6 100 2 99 6 99 1 99 7 102 8 101 6 102 4 101 5 102 1 102 2 1x10 Λ 6 pfu pfu Group 5 mutant wild type 1 x10 Λ 6 100 96 6 94 8 96 0 98 9 99 2 99 9 99 5 98 8 101 8 102 6 102 2 100 2 101 6 102 1 3x10 Λ 4 pfu pfu Group 6 mutant wild type lx10 Λ b 100 97 5 96 2 95 1 94 7 94 4 95 6 97 5 96 8 99 1 98 5 98 6 97 8 98 2 99 9 1X10 Λ 3 pfu pfu Group 7 PBS wild type 1 x10 Λ b 100 97 2 92 0 88 9 87 3 87 0 86 3 86 8 86 0 87 0 86 9 87 0 86 1 86 6 87 0 pfu Health Score - mean per group Challenge 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Gioup 4 mutant wild type 1 x lU Λ 6 0 00 0 00 0 50 0 17 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 0 00 1x10 Λ 6 pfu μtu Group 5 mutant wild type 1 x10 A 6 0 00 0 00 1 33 0 83 0 83 0 00 0 00 0 33 0 00 0 00 0 00 0 00 0 00 0 00 0 00 3x10 Λ 4 pfu pfu - Group 6 mutant wild type 1x10 Λ 6 0 00 0 00 2 17 2 00 1 83 2 00 2 17 1 67 1 33 1 33 1 33 1 33 1 33 1 33 1 33 1X1 ϋ Λ 3 pfu pfu Group 7 PBS wild type 1x10 Λ 6 0 00 0 00 4 00 4 33 5 50 5 67 5 83 5 33 5 33 5 33 5 33 5 33 5 33 5 33 5 33 > pfu

Claims: CLAIMS 1. A negative-sense single stranded RNA vims attenuated by replacement of the poly U track in a genomic nucleic acid by a poly A track which is capable of being copied to provide a poly U tail for mRNA transcribed from the nucleic acid. 2. A vims according to claim 1 in which the poly A track is copied by a reiterative mechanism. 3. A vims according to claim 1 or 2 which is an influenza vims. 4. A vims according to claim 3 which is an influenza A, B or C vims. 5. A vims according to claim 3 or 4 in which the nucleic acid encodes a neuraminidase. 6. A vims according to claim 3, 4, or 5 in which the nucleic acid is a mutated native influenza vims genomic RNA segment. 7. A vims according to any one of claims 3 to 6 which exhibits at least about a 0.5 log reduction in plaque titre compared to the parent wild type vims on MDCK cells. 8. A vims according to any one of the preceding claims which additionally comprises a heterologous coding sequence capable of being expressed in target cells. 9. A vims according to claim 8 wherein said heterologous coding sequence encodes an antigenic peptide or polypeptide capable of stimulating an immune response to a pathogenic agent. 10. A nucleic acid as defined in claim 1, 5 or 6. 11. A DNA capable of transcription to provide a nucleic acid according to claim 10. 12. A plasmid containing a DNA as defined in claim 11 A ribonucleoprotein (RNP) complex wherein a nucleic acid as defined in claim 10 is complexed with polymerase proteins and nucleoprotein of an influenza vims for use in preparing an attenuated vims as claimed in any one of claims 3 to 9 An ex vivo cell infected by a vims as defined in any one of claims 1 to 9 A vaccine comprising a vims as claimed in any one of claims 1 to 9 A vaccine as claimed in claim 15 which comprises a vims as defined in claim 9 and which is capable of stimulating an immune response to an influenza vims and a second pathogenic agent other than an influenza vims A pharmaceutical composition comprising a vims as defined in claim 8 or 9 in combination with a pharmaceutically acceptable carrier or diluent for delivery of said heterologous coding sequence to target cells A pharmaceutical composition comprising cells infected with a vims according to claim 8 or 9 in combination with a pharmaceutically acceptable carrier or diluent A method of preparing a vims according to any one of claims 1 to 9 which comprises providing in a host cell the genomic nucleic acid segments for said vims under conditions whereby said segments are packaged into a viral particle Use of a vims as claimed in any one of claims 1 to 9 as a helper vims to rescue an influenza vims genomic nucleic acid segment in cells, wherein vimses produced containing said nucleic acid segment are selected on the basis of increased growth compared with the helper vims on cells of a selected type A method of stimulating an immune response against an influenza vims, optionally together with stimulation of an immune response against one or more further pathogenic agents, which comprises administering in an immunising mode an attenuated influenza vims as claimed in any one of claims 1 to 9 22. A method of delivering a heterologous coding sequence to cells which comprises infecting said cells with a vims according to claim 8 or 9 carrying said sequence. 23. Use of a mutation in a poly A track to attenuate a vims.

Inventors: BROWNLEE GEORGE GOW, FODOR ERVIN, POON LEO, BROWNLEE, GEORGE, GOW, FODOR, ERVIN, POON, LEO
Applicants: BROWNLEE GEORGE GOW, FODOR ERVIN, ISIS INNOVATION, POON LEO, BROWNLEE, GEORGE, GOW, FODOR, ERVIN, ISIS INNOVATION LIMITED, POON, LEO
Application year: 2000
Main classification: C12N7
IPC codes: A61K39, A61P31, C07K14, C07K19, C12N5, C12N7, C12N15